Yes, monitor TSH and cortisol routinely in patients receiving low-dose nivolumab; HbA1c monitoring is reasonable but less critical.
For patients on nivolumab therapy, TSH should be checked every 4-6 weeks as part of routine monitoring, and morning cortisol with ACTH should be evaluated at baseline and when symptoms suggest adrenal insufficiency. 1 The FDA label explicitly states to "evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment" for immune-mediated endocrinopathies. 2
Thyroid Monitoring (TSH)
- Check TSH every 4-6 weeks during nivolumab therapy, even in asymptomatic patients 1
- Include free T4 (FT4) alongside TSH when patients are symptomatic, as TSH alone can miss central hypothyroidism from hypophysitis 1
- Thyroid dysfunction is common with immune checkpoint inhibitors, occurring in approximately 10% of patients 1
Critical pitfall: Low TSH with low FT4 indicates central hypothyroidism from hypophysitis, not hyperthyroidism. Always check both values when interpreting abnormal results. 1
Cortisol/ACTH Monitoring
While guidelines recommend TSH monitoring routinely, cortisol screening is less standardized but increasingly recognized as important:
- Current practice shows significant gaps: only 1 of 185 patients receiving ipilimumab-nivolumab had baseline and interval cortisol/ACTH testing, yet 9.1% developed secondary adrenal insufficiency 3
- Morning (8 AM) cortisol with ACTH should be checked at baseline and when symptoms develop (fatigue, nausea, vomiting, hypotension, hyponatremia) 1, 4, 5
- ESMO guidelines specifically recommend checking 9 AM cortisol, ACTH, and other pituitary hormones when hypophysitis is suspected 4
Critical consideration: Adrenal insufficiency can present insidiously and may occur months after discontinuing nivolumab 6. The most common presenting symptom is fatigue (35%), followed by nausea (29%) and vomiting (24%) 3. These nonspecific symptoms are easily confused with cancer-related symptoms or other treatment effects.
Essential safety rule: If both cortisol and thyroid hormone deficiencies are present, always replace hydrocortisone FIRST before initiating thyroid hormone replacement 1. Starting thyroid hormone when cortisol is low can precipitate life-threatening adrenal crisis by increasing cortisol metabolism. 1
HbA1c Monitoring
HbA1c monitoring is less emphasized in guidelines but has clinical rationale:
- Immune-related diabetes mellitus occurs in 1-2% of patients on checkpoint inhibitors 4
- Can present as fulminant type 1 diabetes with rapid onset, even with normal HbA1c initially (one case showed glucose 473 mg/dL with HbA1c only 6.9%) 7
- Consider baseline HbA1c and periodic monitoring, especially if symptoms of hyperglycemia develop (polyuria, polydipsia, nausea, vomiting) 1
Practical Monitoring Algorithm
Baseline (before starting nivolumab):
- TSH (mandatory per FDA label) 2
- Morning cortisol and ACTH (recommended based on emerging evidence) 4, 3
- HbA1c or fasting glucose (reasonable)
During treatment:
- TSH every 4-6 weeks routinely 1
- Morning cortisol/ACTH when new fatigue, weakness, nausea, hypotension, or hyponatremia develops 5, 6
- Monitor serum sodium, blood pressure, and fasting glucose as indirect markers of adrenal function 5
After discontinuation:
The dose of nivolumab (whether "low-dose" or standard) does not change these monitoring recommendations, as immune-related endocrinopathies can occur at any dose level.